|
Exdensur is now the first twice-yearly add-on maintenance therapy approved for use in severe eosinophilic asthma.
|
 |
|
Sanofi has agreed $1.7bn and $1.04bn licensing deals with Dren Bio and ADEL, respectively.
|
|
|
Harbour is eligible for payments of $90m, with potential development and commercial milestones of up to $1.035bn.
|
|
|
By 2030, the company anticipates employing 1,000 people at its new campus.
|
|
|
Large M&A transactions and bidding wars for Metsera and Avadel announced in H2 2025 reflect a need for large pharma companies to replenish pipelines through M&A ahead of looming patent cliffs.
|
|
|
Targeted patient recruitment can increase the likelihood of trial success and help cultivate use of precision medicine.
|
|
